[go: up one dir, main page]

DK0590789T3 - Excitatoriske aminosyrereceptorantagonister - Google Patents

Excitatoriske aminosyrereceptorantagonister

Info

Publication number
DK0590789T3
DK0590789T3 DK93306745T DK93306745T DK0590789T3 DK 0590789 T3 DK0590789 T3 DK 0590789T3 DK 93306745 T DK93306745 T DK 93306745T DK 93306745 T DK93306745 T DK 93306745T DK 0590789 T3 DK0590789 T3 DK 0590789T3
Authority
DK
Denmark
Prior art keywords
alkyl
chr
hydrogen
chem
phenyl
Prior art date
Application number
DK93306745T
Other languages
English (en)
Inventor
Paul Leslie Ornstein
Macklin Brian Arnold
Nancy Kay Augenstein
Carl Franklin Bertsch
Marvin Martin Hansen
Allen Robert Harkness
Bret Eugene Huff
William Henry Walker Lunn
Michael John Martinelli
Darryle Darwin Schoepp
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0590789T3 publication Critical patent/DK0590789T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK93306745T 1992-09-03 1993-08-25 Excitatoriske aminosyrereceptorantagonister DK0590789T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/939,780 US5284957A (en) 1992-09-03 1992-09-03 Excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
DK0590789T3 true DK0590789T3 (da) 2004-03-22

Family

ID=25473721

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93306745T DK0590789T3 (da) 1992-09-03 1993-08-25 Excitatoriske aminosyrereceptorantagonister

Country Status (26)

Country Link
US (7) US5284957A (da)
EP (1) EP0590789B9 (da)
JP (1) JP3601840B2 (da)
KR (1) KR100274367B1 (da)
CN (1) CN1043762C (da)
AT (1) ATE234287T1 (da)
AU (1) AU656482B2 (da)
BR (1) BR9303495A (da)
CA (2) CA2484248A1 (da)
CZ (1) CZ285049B6 (da)
DE (1) DE69332754T2 (da)
DK (1) DK0590789T3 (da)
ES (1) ES2194844T3 (da)
FI (1) FI933810A7 (da)
HU (2) HU224015B1 (da)
IL (1) IL106809A (da)
MX (1) MX9305294A (da)
MY (1) MY131442A (da)
NO (1) NO304072B1 (da)
NZ (1) NZ248513A (da)
PH (1) PH31250A (da)
PL (1) PL173809B1 (da)
PT (1) PT590789E (da)
RU (1) RU2117661C1 (da)
SG (1) SG45319A1 (da)
ZA (1) ZA936231B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087812B1 (es) * 1993-07-02 1997-03-16 Lilly Co Eli Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores.
US5580877A (en) * 1994-04-25 1996-12-03 Merck Sharp & Dohme Ltd. Pyrazolo-quinoline derivatives for treating cerebral ischemia
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
BR9611479B1 (pt) * 1995-11-13 2009-01-13 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.
US5723414A (en) * 1996-01-24 1998-03-03 Rohm And Haas Company 5-aryl-isoxazolinones and herbicidal use thereof
ES2198546T3 (es) 1996-05-15 2004-02-01 Pfizer Inc. 4(3h)-quinazolinonas 2,3,6 trisustituidas.
DK0807633T3 (da) * 1996-05-15 2002-11-25 Pfizer Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
ID23013A (id) 1997-04-07 1999-12-30 Lilly Co Eli Bahan-bahan farmakologi
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
WO1999044612A1 (en) 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
TW513301B (en) * 1999-03-01 2002-12-11 Novartis Ag Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders
KR20020024300A (ko) 1999-07-06 2002-03-29 피터 지. 스트링거 편두통을 치료하기 위한 선택적 ｉＧｌｕＲ5 수용체 길항제
DE60002733T2 (de) * 1999-07-06 2004-03-18 Eli Lilly And Co., Indianapolis Diester prodrugs von decahydroischinoline-3-carbonsäure
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US6579886B2 (en) 1999-12-22 2003-06-17 Eli Lilly And Company Selective iglur5 receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
DZ3460A1 (fr) * 2001-01-05 2002-07-11 Lilly Co Eli Antagonistes du recepteur d'acide amine excitateur
EP1351952A2 (en) * 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1351951A2 (en) 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0106858D0 (en) * 2001-03-20 2001-05-09 Perkins Engines Co Ltd An accessory drive for driving an engine accessory
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7091249B2 (en) * 2001-12-26 2006-08-15 University Of Iowa Research Foundation Drugs for spinal anesthesia
AU2003219955A1 (en) * 2002-03-22 2003-10-13 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
MXPA04009857A (es) 2002-04-26 2004-12-07 Lilly Co Eli Derivados de ester con un acido decahidroisoquinoli-3-carboxilico como analgesicos.
WO2003090780A1 (en) * 2002-04-26 2003-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Direct cell target analysis
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
US20060220794A1 (en) * 2005-04-04 2006-10-05 Jeffrey Zhu Phase modulation for backscatter transponders
WO2007101116A2 (en) * 2006-02-24 2007-09-07 The Trustees Of Columbia University In The City Of New York Glur2 receptor modulators
US20080108622A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20080108603A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20090270508A1 (en) * 2007-02-23 2009-10-29 James Eric Gouaux GluR2 receptor modulators
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CN101812031A (zh) * 2010-04-29 2010-08-25 南通市华峰化工有限责任公司 一种5-羟烷基四氮唑的高压生产方法
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
KR20160048988A (ko) 2013-09-06 2016-05-04 인셉션 2 인코퍼레이티드 트라이아졸론 화합물 및 이의 용도
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
JP7653184B2 (ja) * 2020-07-02 2025-03-28 シー ファーマシューティカルズ エルエルシー ６‐（２‐（２ｈ‐テトラゾール‐５‐イル）エチル）‐６‐フルオロデカヒドロイソキノリン‐３‐カルボキシル酸及びそのエステル誘導体の医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK704488D0 (da) * 1988-12-19 1988-12-19 Novo Industri As Nye n-substituerede azaheterocykliske carboxylsyrer
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4824959A (en) * 1988-02-18 1989-04-25 Bristol-Myers Company Intermediates for antihypercholesterolemic tetrazole compounds
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
PL173809B1 (pl) 1998-05-29
EP0590789A1 (en) 1994-04-06
CA2484248A1 (en) 1994-03-04
FI933810A0 (fi) 1993-08-31
PT590789E (pt) 2003-07-31
NO304072B1 (no) 1998-10-19
EP0590789B1 (en) 2003-03-12
HK1013989A1 (en) 1999-09-17
US5648492A (en) 1997-07-15
HU224015B1 (hu) 2005-04-28
AU4600393A (en) 1994-03-10
NO933100L (no) 1994-03-04
NZ248513A (en) 1996-02-27
HUT65228A (en) 1994-05-02
CA2104909C (en) 2005-01-11
HU9302453D0 (en) 1993-11-29
JPH06199802A (ja) 1994-07-19
CA2104909A1 (en) 1994-03-04
BR9303495A (pt) 1994-03-22
MX9305294A (es) 1994-06-30
KR100274367B1 (ko) 2000-12-15
US5670516A (en) 1997-09-23
SG45319A1 (en) 1998-01-16
FI933810L (fi) 1994-03-04
NO933100D0 (no) 1993-08-31
JP3601840B2 (ja) 2004-12-15
US5284957A (en) 1994-02-08
KR940007021A (ko) 1994-04-26
ZA936231B (en) 1995-02-27
DE69332754T2 (de) 2004-06-17
MY131442A (en) 2007-08-30
CZ174593A3 (en) 1994-03-16
US5675008A (en) 1997-10-07
PH31250A (en) 1998-06-18
US5637712A (en) 1997-06-10
CN1091129A (zh) 1994-08-24
FI933810A7 (fi) 1994-03-04
US5399696A (en) 1995-03-21
AU656482B2 (en) 1995-02-02
HU211992A9 (en) 1996-01-29
ES2194844T3 (es) 2003-12-01
RU2117661C1 (ru) 1998-08-20
ATE234287T1 (de) 2003-03-15
EP0590789B9 (en) 2004-02-04
IL106809A (en) 1999-03-12
CZ285049B6 (cs) 1999-05-12
CN1043762C (zh) 1999-06-23
US5606062A (en) 1997-02-25
DE69332754D1 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
DK0590789T3 (da) Excitatoriske aminosyrereceptorantagonister
NO169286C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater
ATE108791T1 (de) Neue 4-oxobenzotriazine und 4-oxochinazoline.
DE3762618D1 (de) Amidderivate.
MX19368A (es) Procedimiento para la preparacion de derivados heterociclicos que contienen nitrogeno benzofusionado y compuesto obtenido.
EA200000336A1 (ru) Антагонисты рецептора витронектина
ID23954A (id) Tetrahidrogama-karbolin
NO905172L (no) Aminokarbonylkarbamater beslektet med fysostigmin og fremgangsmaate for fremstilling derav.
DE68926981D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung
ATE84545T1 (de) Derivate des alpha-anp und ihre herstellung.
DK0541263T3 (da) 5-Piperazinylalkyl-1,5-benzothiazepinoner, der er nyttige som calciumantagonister
DK0648762T3 (da) Bicykliske forbindelser som excitatoriske aminosyrereceptorantagonister
HU895648D0 (en) Process for the preparation of n,n-disubstituted diaryl-alkancarboxylic acid amide derivatives and pharmaceutical compositions containing such compounds
ATE113950T1 (de) 4,5,6,11-tetrahydrobenzo(6,7>-cycloocta(1,2- b>thiophen-6,11-imine und 6,11-dihydrobenzo(6,7>- cycloocta(1,2-b>thiophen-6,11-imine.
PT911336E (pt) Derivados do acido piridonacarboxilico e intermediarios para a sua sintese
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.
IT1274040B (it) Composizioni farmaceutiche per la prevenzione e/o il trattamento di disturbi gastrointestinali inclusa l'ulcera